학술논문

First-Line Bevacizumab (Bev) Combination Therapy in Triple-Negative (TN) Locally Recurrent/Metastatic Breast Cancer (LR/MBC): Subpopulation Analysis of Study MO19391 in > 2000 Patients (Pts).
Document Type
Journal
Source
CANCER RESEARCH; DEC 15 2009, 69 24, p854S-p854S, 1p. Supplement: 3
Subject
Language
English
ISSN
00085472